| Metric | Value (₹ Cr) | Q2 FY26 | Q3 FY25 |
|---|---|---|---|
| Revenue | 494.30 | 55.2% | 10.4% |
| Total Income | 497.10 | 55.1% | 10.2% |
| Expenditure | 468.30 | 27.5% | 9.5% |
| PBT | -9.20 | 80.4% | 138.7% |
| Net Profit | -5.90 | 83.1% | 134.3% |
| OPM | 9.04% | 6.78pp | 16.12pp |
| NPM | -1.19% | 9.70pp | 5.00pp |
| EPS | 0.48 | 65.5% |
Hikal Ltd. Reports 10% YoY Growth in Q3 FY26 Revenue, Improves EBITDA Margin
11 Feb 2026 · 11 Feb, 5:10 pm
Summary
Hikal Ltd., a preferred long-term partner for leading global life sciences companies, announced its unaudited financial results for the quarter and nine months ended 31st December 2025. The company reported a YoY growth in revenue and EBITDA margin.
Key Highlights
- 1
Revenue registered a YoY growth of 10% to 2 494 crores
- 2
EBITDA registered a YoY growth of 15% to 2 83 crores
- 3
EBITDA Margin improved by 70 bps on YoY basis to 16.8%
- 4
PBT before exceptional item registered a YoY growth of 22% to % 29 crores
- 5
Balance sheet strengthened, improved debt-equity ratio of 0.58x
Management Comments
Jai Hiremath
Executive Chairman, Hikal Ltd.
Q3 FY26 marks a return to positive operational performance for our company. Following the regulatory cycle triggered in early 2025, we have transitioned from remediation to recovery and are now positioned for sustainable, higher-quality growth.
Informational and educational content only. Not investment advice.